Stockscreener 앱 받기
1.75
0.57%
-0.01
시간 외 거래:
1.78
0.03
+1.71%
전일 마감가:
$1.76
열려 있는:
$1.76
하루 거래량:
64,284
Relative Volume:
0.42
시가총액:
$8.01M
수익:
$895.50K
순이익/손실:
$-26.30M
주가수익비율:
-1.0671
EPS:
-1.64
순현금흐름:
$-23.84M
1주 성능:
-1.13%
1개월 성능:
-12.06%
6개월 성능:
-69.51%
1년 성능:
-87.40%
1일 변동 폭
$1.72
$1.85
1주일 범위
$1.6978
$1.90
52주 변동 폭
$1.30
$18.40
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
1.75 | 8.24M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | Maxim Group | Buy |
| 2024-11-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | 개시 | H.C. Wainwright | Buy |
Mainz Biomed N V 주식(MYNZ)의 최신 뉴스
What’s next for Mainz Biomed N.V. stockJuly 2025 Recap & Weekly Breakout Watchlists - thegnnews.com
Can Mainz Biomed N.V. navigate macro headwindsRate Cut & Target Return Focused Stock Picks - thegnnews.com
Why Mainz Biomed N.V. stock attracts strong analyst attention2025 Retail Activity & Community Consensus Trade Alerts - beatles.ru
What are Mainz Biomed N.V.’s recent SEC filings showing2025 Market Sentiment & Risk Controlled Swing Alerts - sundaytimes.kr
Is Mainz Biomed N.V. a speculative investmentJuly 2025 PreEarnings & AI Powered Buy/Sell Recommendations - newsyoung.net
Mainz Biomed Wins Swiss Regulatory Approval for Colorectal Cancer Screening Test - MarketScreener
Mainz Biomed’s colorectal cancer test receives Swiss regulatory approval - Investing.com India
Mainz Biomed’s colorectal cancer test receives Swiss regulatory approval By Investing.com - Investing.com Nigeria
New Non-Invasive Colon Cancer Test Gets Swiss Green Light, Targets 2.8M Potential Users - Stock Titan
Is Mainz Biomed N.V. stock reversal real or fakeShort-Term Profit Alert With Entry Forecast - Newser
Mainz Biomed Secures $3 Million Through Securities Purchase Agreement - The Globe and Mail
Mainz Biomed Secures $3 Million in Funding Through Securities Purchase Agreement - AInvest
Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit - MarketScreener
Mainz Biomed raises $3M in follow-on offering. - AInvest
Mainz Biomed Prices $3.0M Follow-On Offering of Over 2.2M Units Including Ordinary Shares and Series A Warrants - 富途牛牛
Mainz Biomed Raises $3M in Follow-On Offering, Expects to Close on August 5 - AInvest
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
What is Mainz Biomed N.V. company’s growth strategySuperior portfolio returns - Jammu Links News
Should I hold or sell Mainz Biomed N.V. stock in 2025Achieve rapid capital gains with smart investing - Jammu Links News
Is Mainz Biomed N.V. stock overvalued or undervaluedGet alerts on high-potential market moves - Jammu Links News
What institutional investors are buying Mainz Biomed N.V. stockGet real-time updates on market movers - Jammu Links News
What is the risk reward ratio of investing in Mainz Biomed N.V. stockSkyrocketing returns - Jammu Links News
Why is Mainz Biomed N.V. stock attracting strong analyst attentionBuild wealth steadily with proven investment strategies - Jammu Links News
How does Mainz Biomed N.V. compare to its industry peersGet alerts on the hottest market movers - Jammu Links News
What is the dividend policy of Mainz Biomed N.V. stockRapid return acceleration - Jammu Links News
Does Mainz Biomed N.V. stock perform well during market downturnsTremendous return on equity - Jammu Links News
How strong is Mainz Biomed N.V. company’s balance sheetUnprecedented growth rates - Jammu Links News
What catalysts could drive Mainz Biomed N.V. stock higher in 2025Capitalize on market trends with confidence - Jammu Links News
How many analysts rate Mainz Biomed N.V. as a “Buy”Advanced Screener Planner For 2025 - Jammu Links News
Mainz Biomed Announces Sale of 1.47 Million Ordinary Units to Bolster Financial Position and Support Growth Initiatives - AInvest
What are Mainz Biomed N.V. company’s key revenue driversDaily Trading Outlook With Proven Results - Jammu Links News
Chartists See Breakout Potential in Mainz Biomed N.V.Real Trader Watchlist of Hot Stocks Released - metal.it
What are the technical indicators suggesting about Mainz Biomed N.V.Stay ahead with advanced stock screening tools - Jammu Links News
What institutions are buying Mainz Biomed N.V. stock nowFree Stock Market Beginners Guide - metal.it
Mainz Biomed N.V. Stock Analysis and ForecastStrong return on assets - Jammu Links News
Mainz Biomed N V (MYNZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.05%
1.90%
자본화:
|
볼륨(24시간):